WuXi PharmaTech to Build $100 Million R&D Center in Wuhan

WuXi PharmaTech will spend $100 million to build a new R&D facility in the central China city of Wuhan. The company will construct a 40,000 sq meter CRO facility in the Wuhan National Biological Industry Base (Optics Valley of BioLake). Wuhan sources told ChinaBio® that a cooperative agreement between WuXi and the Wuhan Biological Base was signed on August 9. More details.... Stock Symbol: (NYSE: WX)